LONG BEACH, Calif. — Oral gildeuretinol helped patients with Stargardt disease maintain visual acuity for up to 7 years of treatment, according to a study.
Kenneth Fan, MD, MBA, discussed interim data from the TEASE-3 study at the American Society of Retina Specialists annual meeting.
“What we presented was essentially data looking at gildeuretinol, which is an investigational treatment for Stargardt disease, which reduces vitamin A dimerization and therefore reduces A2E and lipofuscin accumulation in photoreceptors and [retinal pigment epithelium],” Fan told Healio. “It